The ASCO Post Podcast

Latest Episodes:

Multiple Myeloma Research From the ASCO20 Virtual Scientific Program Jul 02, 2020

Show notes

This week, we’ll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.

COVID-19 Research From the ASCO20 Virtual Scientific Program Jun 26, 2020

Show notes

With this week bringing record highs of COVID-19 infection across the nation, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.

Findings in Prostate Cancer From the ASCO20 Virtual Scientific Program Jun 19, 2020

Show notes

We're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program.

Plenary Research From the ASCO20 Virtual Scientific Program: Part 2 Jun 12, 2020

Show notes

This week, we’ll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program.

Plenary Research From the ASCO20 Virtual Scientific Program: Part 1 Jun 05, 2020

Show notes

This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.

Coagulation Issues in Patients With COVID-19: Part 2 May 29, 2020

Show notes

In part 2 of our conversation with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy, Dr. Abutalib outlines methods of treatment and prevention for coagulation issues in patients with COVID-19, and summarizes the hematologic consequences of the virus.

Coagulation Issues in Patients With COVID-19: Part 1 May 21, 2020

Show notes

This week, we spoke with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy. Dr. Abutalib outlines recent data on coagulation issues seen in patients with COVID-19.

Highlights From the AACR Virtual Annual Meeting May 12, 2020

Show notes

This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper on trends in the locations of tobacco and vape shops.

Does Ibrutinib Offer a Protective Effect Against Pulmonary Injury in Patients With COVID-19? May 05, 2020

Show notes

This week, we’ll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we’ll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline BRCA-mutated breast cancer. Lastly, we’ll review the FDA’s approval of niraparib for patients with advanced ovarian cancer.

Coverage of stories discussed this week on ascopost.com:

Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19

AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial

FDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer

Recent FDA Oncology/Hematology Approvals Apr 28, 2020

Show notes

The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion

FDA Approves Ibrutinib/Rituximab for CLL/SLL

FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer